Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Discontinuation vs. continuation of concomitant methotrexate in patients with rheumatoid arthritis on certolizumab pegol: results from a randomised, controlled trial

Fig. 4

Gastrointestinal symptoms. (A) Estimated means and 95% confidence intervals for Frequency Scale for Symptoms of Gastroesophageal reflux disease (FSSG) score. (B) Proportion of patients with FSSG score ≥ 8. *P < 0.05 between the two groups. CZP: certolizumab pegol; MTX: methotrexate

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us